GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Cash-to-Debt

Marizyme (Marizyme) Cash-to-Debt : 0.01 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Marizyme's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Marizyme couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Marizyme's Cash-to-Debt or its related term are showing as below:

MRZM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 1.15   Max: No Debt
Current: 0.01

During the past 13 years, Marizyme's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 1.15.

MRZM's Cash-to-Debt is ranked worse than
98.93% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs MRZM: 0.01

Marizyme Cash-to-Debt Historical Data

The historical data trend for Marizyme's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Marizyme Cash-to-Debt Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A 2.20 2.29 0.10 0.01

Marizyme Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.04 0.01 0.02 0.01

Competitive Comparison of Marizyme's Cash-to-Debt

For the Biotechnology subindustry, Marizyme's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Marizyme's Cash-to-Debt falls into.



Marizyme Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Marizyme's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Marizyme's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marizyme  (OTCPK:MRZM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Marizyme Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Marizyme's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme (Marizyme) Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478